Alopecia Treatment Market Insights
Alopecia Treatment Market- Insights
Alopecia also called as hair loss or baldness is very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.
Market Dynamics
Product launches, approvals, and robust pipeline of novel products is expected to be the major driver of growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market. In May 2018, Histogen, Inc., received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss.
HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in market. For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in Peoples Republic of China.
Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of market. For instance, according to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.
Key features of the study:
- This report provides in-depth analysis of alopecia treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Daiichi Sankyo, Inc., Cipla Limited, and others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the alopecia treatment market
Detailed Segmentation:
- Global Alopecia Treatment Market, By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- Global Alopecia Treatment Market, By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- Global Alopecia Treatment Market, By Gender:
- Male
- Female
- Global Alopecia Treatment Market, By Route of Administration:
- Oral
- Topical
- Injectable
- Global Alopecia treatment market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Alopecia treatment market, By Geography:
- North America
- By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- By Gender
- Male
- Female
- By Route of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- By Disease Type :
- Europe
- By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- By Gender
- Male
- Female
- By Route of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- By Disease Type :
- Asia Pacific
- By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- By Gender
- Male
- Female
- By Route of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- By Disease Type :
- Latin America
- By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- By Gender
- Male
- Female
- By Route of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Disease Type :
- Middle East
- By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- By Gender
- Male
- Female
- By Route of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Disease Type :
- Africa
- By Disease Type :
- Androgenic Alopecia
- Alopecia Areata
- Ciatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- By Drug Type:
- Vasodilators
- Minoxidil
- 5-Alpha Reductase Inhibitors
- Finasteride
- Corticosteroids
- Immunosuppressants
- Cyclosporine
- Others
- Others
- Vasodilators
- By Gender
- Male
- Female
- By Route of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Central Africa
- South Africa
- North Africa
- By Disease Type :
- Company Profiles
- Histogen, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Aclaris Therapeutics, Inc.
- Concert Pharmaceuticals, Inc.
- HCell Inc.
- GlaxoSmithKline plc.
- Daiichi Sankyo, Inc.
- Cipla Limited
- Histogen, Inc.*
- North America
“*” marked represents similar segmentation in other categories in the respective section.
Alopecia Treatment Market Insights
Previous Posts
